Tenapanor Hydrochloride is a small molecule sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. By locally inhibiting… Read more
Tenapanor Hydrochloride is a small molecule sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor approved for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults. By locally inhibiting these sodium channels in the gastrointestinal tract, the drug reduces sodium and water absorption, thereby improving bowel regularity and stool consistency. This category includes high-quality Tenapanor Hydrochloride reference standards, along with its specific impurities, metabolites, and stable isotope-labelled compounds. Pharmaceutical and analytical laboratories rely on these materials for critical tasks such as impurity profiling, method validation, and rigorous quality control throughout the drug development and regulatory approval process. Utilizing certified standards ensures accurate quantification and identification of degradants or process-related impurities, supporting comprehensive stability studies and helping to confirm the safety and efficacy of the final pharmaceutical product in compliance with global standards.